Michael E. Dodge
University of Texas Southwestern Medical Center
12 Papers
72 Citations
Michael E. Dodge is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Wnt signaling pathway & LRP6. The author has an hindex of 12, co-authored 12 publications. Previous affiliations of Michael E. Dodge include University of Texas at Dallas & University of Texas System.
Chat about Author
Papers
Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer
Baozhi Chen,Michael E. Dodge,Wei Tang,Jianming Lu,Zhiqiang Ma,Chih Wei Fan,Shuguang Wei,Wayne Hao,Jessica A. Kilgore,Noelle S. Williams,Michael G. Roth,James F. Amatruda,Chuo Chen,Lawrence G. Lum +13 more
TL;DR: Two novel classes of small molecules are discovered that disrupt Wnt pathway responses and contribute to Wnt-independent signal transduction pathways and thus could be broadly exploited for chemical genetics and therapeutic goals.
1.4K
Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on Notch signaling
James P. Sullivan,Monica Spinola,Michael E. Dodge,Maria Gabriela Raso,Carmen Behrens,Boning Gao,Katja Schuster,Chunli Shao,Jill E. Larsen,Laura A. Sullivan,Sofia Honorio,Yang Xie,Pier Paolo Scaglioni,J. Michael DiMaio,Adi F. Gazdar,Jerry W. Shay,Ignacio I. Wistuba,John D. Minna +17 more
TL;DR: Findings indicate that ALDH selects for a subpopulation of self-renewing NSCLC stem-like cells with increased tumorigenic potential, that NSCLCs harboring tumor cells with ALDH1A1 expression have inferior prognosis, and that AL DH 1A1 and CD133 identify different tumor subpopulations.
433
A genome-wide RNAi screen for Wnt/β-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer
Wei Tang,Michael E. Dodge,Deepika Gundapaneni,C. H. Michnoff,Michael G. Roth,Lawrence G. Lum +5 more
TL;DR: Surprisingly, it is found that the presumed cancer-promoting gene TCF7L2 functions instead as a transcriptional repressor that restricts colorectal cancer (CRC) cell growth.
190
Pharmacological targeting of the pseudokinase Her3
Ting Xie,Sang M in Lim,Kenneth D. Westover,Michael E. Dodge,Dalia Ercan,Scott B. Ficarro,Durga Udayakumar,Deepak Gurbani,Hyun Seop Tae,Steven M. Riddle,Taebo Sim,Jarrod A. Marto,Pasi A. Jänne,Craig M. Crews,Nathanael S. Gray +14 more
TL;DR: It is demonstrated that covalent modification of Her3 inhibits Her3 signaling but not proliferation in some Her3 dependent cancer cell lines, and suggests that small molecules will be capable of perturbing the biological function of She3 and the approximately 60 other pseudokinases found in human cells.
Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma
Marzia Capelletti,Michael E. Dodge,Dalia Ercan,Peter S. Hammerman,Seung-Il Park,Jhingook Kim,Hidefumi Sasaki,David M. Jablons,Doron Lipson,Lauren Young,Phil Stephens,Vincent A. Miller,Neal I. Lindeman,Kiara J. Munir,William G. Richards,Pasi A. Jänne +15 more
TL;DR: FGFR3–TACC3 rearrangements occur in a subset of patients with lung adenocarcinoma, which should be considered for clinical trials featuring FGFR inhibitors.
102